Search research articles
Contact Us
Filters
Showing results (81-90 of 320) with videos related to
Page
of 32
Sort By:
Transfusion
|
February 1, 2003
Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process
Boris Zavizion, Diana Serebryanik, Irina Serebryanik, et al.
International Journal of Surgical Pathology
|
July 3, 2015
DOG1 Expression in Low-Grade Fibromyxoid Sarcoma: A Study of 11 Cases, With Molecular Characterization
Khin Thway, Wen Ng, Charlotte Benson, et al.
The American Journal of Orthopsychiatry
|
January 14, 2012
Mental illness, violence risk, and race in juvenile detention: implications for disproportionate minority contact
Rani A Desai, Paul R Falzer, John Chapman, et al.
Journal of General Internal Medicine
|
April 20, 2023
Estimating the Primary Care Workforce for Medicare Beneficiaries Using an Activity-Based Approach
Monica O'Reilly-Jacob, John Chapman, Senthil Veerunaidu Subbiah, et al.
Journal of Lipid Research
|
February 18, 2003
A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression
Wilfried Le Goff, Maryse Guerin, M John Chapman, et al.
Archives of Biochemistry and Biophysics
|
May 26, 2009
Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl
Sandrine Chantepie, Ernst Malle, Wolfgang Sattler, et al.
Pharmacology & Therapeutics
|
February 16, 2010
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
M John Chapman, Jan S Redfern, Mark E McGovern, et al.
Nature Reviews. Drug Discovery
|
May 24, 2014
HDL-targeted therapies: progress, failures and future
Bronwyn A Kingwell, M John Chapman, Anatol Kontush, et al.
Journal of Clinical Lipidology
|
March 26, 2018
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP
M John Chapman, Alexina Orsoni, Paul Robillard, et al.
Current Opinion in Cardiology
|
July 7, 2011
Optimal pharmacotherapy to combat the atherogenic lipid triad
M John Chapman, Jan S Redfern, Mark E McGovern, et al.
Page
of 32
Search research articles
Search
Showing results (81-90 of 320) with videos related to
Sort By:
Page
of 32
Transfusion
|
February 1, 2003
Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process
Boris Zavizion, Diana Serebryanik, Irina Serebryanik, et al.
International Journal of Surgical Pathology
|
July 3, 2015
DOG1 Expression in Low-Grade Fibromyxoid Sarcoma: A Study of 11 Cases, With Molecular Characterization
Khin Thway, Wen Ng, Charlotte Benson, et al.
The American Journal of Orthopsychiatry
|
January 14, 2012
Mental illness, violence risk, and race in juvenile detention: implications for disproportionate minority contact
Rani A Desai, Paul R Falzer, John Chapman, et al.
Journal of General Internal Medicine
|
April 20, 2023
Estimating the Primary Care Workforce for Medicare Beneficiaries Using an Activity-Based Approach
Monica O'Reilly-Jacob, John Chapman, Senthil Veerunaidu Subbiah, et al.
Journal of Lipid Research
|
February 18, 2003
A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression
Wilfried Le Goff, Maryse Guerin, M John Chapman, et al.
Archives of Biochemistry and Biophysics
|
May 26, 2009
Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl
Sandrine Chantepie, Ernst Malle, Wolfgang Sattler, et al.
Pharmacology & Therapeutics
|
February 16, 2010
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
M John Chapman, Jan S Redfern, Mark E McGovern, et al.
Nature Reviews. Drug Discovery
|
May 24, 2014
HDL-targeted therapies: progress, failures and future
Bronwyn A Kingwell, M John Chapman, Anatol Kontush, et al.
Journal of Clinical Lipidology
|
March 26, 2018
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP
M John Chapman, Alexina Orsoni, Paul Robillard, et al.
Current Opinion in Cardiology
|
July 7, 2011
Optimal pharmacotherapy to combat the atherogenic lipid triad
M John Chapman, Jan S Redfern, Mark E McGovern, et al.
Page
of 32